Akari Therapeutics, Plc (AKTX)
| Market Cap | 10.69M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.77M |
| Shares Out | 45.27M |
| EPS (ttm) | -0.57 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 531,310 |
| Open | 0.269 |
| Previous Close | 0.259 |
| Day's Range | 0.233 - 0.269 |
| 52-Week Range | 0.218 - 1.730 |
| Beta | 0.31 |
| Analysts | Strong Buy |
| Price Target | 2.53 (+971.13%) |
| Earnings Date | Apr 15, 2026 |
About AKTX
Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads include PH5, which inhibits DNA mismatch repair (MMR... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for AKTX stock is "Strong Buy." The 12-month stock price target is $2.53, which is an increase of 971.13% from the latest price.
News
Akari Therapeutics Appoints Leading Cancer Biology and RNA Expert, Prafulla Gokhale, Ph.D., to Scientific Advisory Board
TAMPA, Fla. and LONDON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncolog...
Akari Therapeutics to Present at the 2026 Biocom Global Partnering & Investor Conference
TAMPA, Fla. and LONDON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel immuno-oncolog...
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
Akari Therapeutics, Plc (AKTX) Discusses New Patent Filing and Expansion of ADC Pipeline for Solid Tumors Transcript
Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company's Expanded ADC Pipeline
CEO Abizer Gaslightwala discusses the Company's recent announcement around its ADC pipeline expansion and IP strategy
Akari Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Tuesday, February 10 th at 1:00 PM EST
Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors
Company expands its ADC pipeline and patent estate for novel, differentiated ADCs New pipeline candidate AKTX-102 leverages Akari's proprietary PH1 spliceosome payload and a novel antibody construct t...
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026
Access the Akari CEO Corner here
Akari Therapeutics to Present at the 2026 Biotech Showcase
In-person presentation on Tuesday, January 13 th at 9:30 AM PT As part of the presentation, Mr. Gaslightwala will provide an overview of Akari's ADC platform, strategic priorities and key milestones f...
Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
TAMPA, Fla. and LONDON, Dec. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel payloads today...
Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial
Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work Akari Will Exclusively Partner With Industry Leader WuXi XDC For This Key IND-enabling Work
Akari Therapeutics Releases Virtual Investor “What This Means” Segment
Watch the “What This Means” video here
Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market
New cash portion of offering includes >20% participation from Directors, Officers and Executive Management New cash portion of offering includes >20% participation from Directors, Officers and Executi...
Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer
Data highlights the ability of Akari's Trop2 ADC, AKTX-101, to kill K-Ras G12V mutated cancer cell lines in preclinical models, potentially addressing one of the most lethal cancers with the lowest su...
Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment
Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for anti...
Akari Therapeutics Announces Release of the Next CEO Corner Segment
Access the Akari CEO Corner here BOSTON and LONDON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payloads for antibody ...
Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript
Akari Therapeutics, Plc ( AKTX) Shareholder/Analyst Call November 18, 2025 11:00 AM EST Company Participants Abizer Gaslightwala - CEO, President & Director Satyajit Mitra - Executive Director & Head...
Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer
More than 20 years of financial and operational leadership in biopharma, including $170M+ in capital raised, global commercialization experience, and a proven track record scaling companies from precl...
Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors
Data presented at the 40 th Annual Society for Immunotherapy of Cancer (SITC) Meeting The spliceosome targeting payload, PH1, demonstrates the ability to induce both cancer cell cytotoxicity and activ...
Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available
Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting on November 7th and 9th Data to be presented at the 40th Annual Society for Immunotherapy of Cancer (SITC) Me...
Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP
Dr. Hurvitz is an international expert in oncology and a recognized clinical research leader with extensive experience leading clinical trials spanning all phases Dr. Hurvitz is an international exper...
Akari Therapeutics Announces Launch of CEO Corner Platform
CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for fut...
Akari Therapeutics Announces $2.5 Million Registered Direct Offering
BOSTON and LONDON, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (the “Company”), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs),...
Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1
BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced...
Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
BOSTON and LONDON, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced...
Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1
Data highlights ability of Akari's ADC payload, PH1, to suppress the levels of the AR-V7 receptor that is responsible for driving hormone refractory prostate cancer progression